Skip to main content

Cabaletta Bio, Inc Investor Event Transcript, Nov 18, 2026

Cabaletta Bio, Inc. (CABA)

Cabaletta Bio said its Rezacel showed a favorable safety profile in the first 71 patients treated. Of the first six dermatomyositis patients past one year, 100% were off immunosuppressants. The company is running a pivotal myositis program in adults and children, and had about $300 million in cash at the end of the third quarter, spending $40 to $50 million per quarter. AI summary

Investor Event Transcript 2026-11-18 For: 2026-12-31
Added on November 18, 2026

Conference Transcript - CABA 2026-11-18

Roger Song, Analyst — Jefferies

All right. Welcome, everyone, to 2026 Jeffrey's Global Healthcare Conference in London. My name is Roger Song, senior analyst covering Smica Biotech in the U.S. It is my pleasure to have the fireside chat with Cabalada. We have a CEO, Stephen, here. Welcome, Stephen.

Stephen, CEO

Yeah, thanks for having us, and thanks for being here.

Roger Song, Analyst — Jefferies

Excellent. It's so timely. We just came back from ACR. We learned quite a bit for the entire cell therapy space in the pneumatic, in general, INI space. So I think a couple of others reported a very impressive durability data, which is new, and then continuously very good safety data as well. We learned a couple of things from off-the-shelf cell-directed therapy, and then we also had some updates from your peers, Autologous Cartier, which we think is different from, you are different from them, or differentiated from them. So maybe, Stephen, you can start with some, what's your key highlights from the ACR, and why, what's missing by the street, and then why? Capulata is standing out from this ACR.

Stephen, CEO

Yes, so ACR was just a terrific culmination of years of work by our team and, frankly, across the industry. I think two clearing events occurred at ACR. One is our clinical data. We demonstrated safety, efficacy, durability, and reliability of our treatment across a variety of autoimmune diseases, and I'll summarize that in a second. But the second clearing event is... That it's our interpretation of the data that's been presented to date, including at ACR, that bispecifics are going to be excellent therapy for patients who want to continue on chronic therapy. They'll step up from what they're on to the new bispecifics that will launch, and if they are interested in continuing to be patients, taking multiple medications, et cetera, that's going to be great therapy. But it will not reset the immune system safely, durably, reliably as we do. I think the other clearing events are around in vivo. It has now been years that we have all seen the in vivo promise. But there has yet to be any real delivery on the promise in autoimmune disease. In cancer, the in vivo's safety and efficacy may turn out to be terrific, and that would be a wonderful thing for patients. But in autoimmunity, we have always believed and we continue to believe, based on our understanding of the risk profile of pro-inflammatory autoimmune patients, that in vivo strategies are going to have an extremely narrow therapeutic index. And that's what we've seen. The clinical data are reflecting more safety issues than efficacy reported over the years. And nothing at ACR changed that. So let me go back now and come back to our ResiCell, our clinical data. So we presented across multiple diseases, first and foremost, safety. If you're not safe in autoimmunity, it's not a drug. In the first 71 patients who we treated, we have what we would consider to be a favorable safety profile, a nice benefit risk for the patients who are in autoimmunity, with about 95% of all patients having either no CRS, that's about 68%, and the remainder towards the 95% having a grade 1 CRS or a fever around day 7. We had a couple of grade two CRSs. We have no grade three or four CRSs in any patient at any point. In those same 71 patients, in the first 10 or so, I think many of you will remember, we had two events that were serious ICANNs events, a grade three and a grade four. Now, both were transient, and both were without long-term sequelae, but that was not the profile we expected, and so we did a lot of work in understanding what was behind those side effects, And we determined and we presented in a peer-reviewed setting, and we presented to FDA that those two ICANNs events, which occurred among our first 10 or 15 patients treated, that they were both in the setting of a recent infection in the patients who were dosed with Rezacel. And it was that recent infection that predisposed them to have an overexposure to our drug. Because of that, we changed our protocol. And since the protocol changed, we've dosed about 60 or more patients over the last year and a half. Resicel has had one grade one eye cans in about 60 patients in a year and a half. And that grade one eye cans was an overnight event that came and went. So we feel as if the safety profile of ResoCell is materially better than and different from everybody else in the industry, as well as other categories of drug who are seeking to hit the bar that we've now established. And the safety then permits us to talk about our efficacy. At one year, we reported that in the first six dermatomyositis patients who'd crossed the one-year time point, 100% of the patients were off of their immunosuppressants. That means they didn't get a single dose of an immunosuppressant during the year. It's not that we cherry-picked into one year and we got good data. All year long, they did not take an immunosuppressant, and they were in terrific shape at the end of the year with moderate to major TIS responses. So please don't make the mistake that this is just like any drug, drugs hit moderate tisks. No, these are patients who are on no medicines, and most of them are off of their steroids as well. In lupus nephritis, we had seven patients who had hit Doris remission and were in a position to be able to take no immunomodulators. Also, most of them were off of their medicines. And the five who had a kidney biopsy to prove whether or not they had lupus nephritis. Even though they had proteinuria, they had no lupus nephritis evidence. So they had major responses in severe refractory lupus patients on no medicines and off of their steroids in most cases, and with a Doris remission and evidence of lupus nephritis gone. And then third, we reported in scleroderma. Scleroderma is an incredibly... This is a devastating autoimmune disease. It has the highest mortality of any of these rheumatologic autoimmune diseases. The risk of death, the risk of death for the 35 or 40-year-old, typically a woman who's diagnosed, at 12 years, she's got a 50-50 shot of seeing her 5-year-old turn 17. Within 12 years, she's going to be dead half the time. Ask yourself whether the burden of Autologous Car T safely delivered. And whether the experience of preconditioning is worth achieving what we gave the patients who were in the trial. So in the patients in the trial, the average improvement. The improvement in lung function, which is usually what kills these patients, they had an improvement for the first time. There's no drug on the market that improves lung function. Improvement of 9% average at one year, and it looks like the RCRIS-50, which is the integrated measure for these patients, of their skin, their organs, etc., was getting better every quarter. Not because our drug was there, because these patients were also not on any immunomodulators, also mostly off of any steroids, right? They were getting better because their bodies were now free to heal and resorb some of the fibrosis that was there. And so you put all this together, the safety, the activity, the efficacy, the durability, the reliability, that if you get the drug, you're going to get the response, we're thrilled. We're absolutely thrilled. And then layer against that, the fact that all of the ghosts that were scaring everybody in the industry about bispecifics or in vivo or other drugs or drug companies were going to exceed the profile of ResoCell, we think all of that has now stated its case. And we'll continue to generate more data. I don't know what tomorrow brings. We'll have our share of side effects. Others will have their share of efficacy. But at the end of the day, if I'm to tell you that there's anything that I'm excited about right now, it's our clinical data and the benefit that we're providing for patients.

Roger Song, Analyst — Jefferies

Excellent. I know you are very excited about the ACR, and I think at those points, I think the street should appreciate, and we will continue to deliver that profile. Okay, let's talk about your pivotal program, because that's another key topic among the investors is you need to make a business case for your sales therapy. The first step, you need to get a label, right? I need to get approval. You have two ongoing period of trial or planned for scleroderma. So my side is... It is the, you know, DM is the key, and ACES is the second subpopulation. It's hard to be 100% CR or the response. How should we think about the commercially attractive profile in terms of the 16-week response and the durability as well, considering this is autologous cell therapy?

Stephen, CEO

Yeah. So in order to focus, as we do, we are running a pivotal program in myositis in the adults and in children. The adult program has 14 patients with dermatomyositis and three patients with antisynthetase syndrome form of myositis. It's widely accepted that the ASIS, antisynthetase for short, the ASIS group, typically is not having durability in many of the patients. When we learned that was after we designed the trial, so we expanded our trial from 14 total to 17 total. We made it so that there were 14 DM patients in the trial so that if all of the ACEs patients did not deliver the durability, we would be able to have the power to demonstrate the efficacy in dermatomyositis alone. And our trial is designed so that that cohort of dermatomyositis patients can both be in an integrated assessment, the TIS score, and in an objective assessment, the MMT8 and other muscle and other measurements that are purely objective would all focus on dermatomyositis. The children, the juvenile dermatomyositis cohort, was a cohort that FDA requested we run. We didn't propose it to them. They proposed it to us. We took the challenge to start to enroll children. Why? Because we're the only company, to our knowledge, that uses weight-based dosing. It's one of the reasons why we think we are safer. And that weight-based dosing strategy has been used now in children. We presented the results from the first juvenile myositis patient. They look just like the adults that I previously talked about. We then shut down visibility into the trial. Because we're treating it as a pivotal trial, because we've had discussions with FDA about the possibility of earning a PRV in response to not six children, which is what we agreed with FDA we would do to seek an indication if the data allowed, but far more than that. And the enthusiasm among the juvenile myositis parents, physicians, and ultimately the benefit to the children, there's an urgency to treat where there are no medications available at all and where their life is essentially major disruption occurs. You know, in second grade, as a parent, you're not going to say, you know what, my kid can't go out and play and can't really work the computer because the hands aren't working as well. And you're not going to say, let's wait until third grade. You're going to go right away. So we think one of the early parts of the market that is going to move very quickly towards our therapy is the pediatric myositis population. There are about 2,000 to 3,000 of these children in the U.S., and we think that it provides a really nice window for us to have a very efficient commercial launch. The key wording in the company is right-sizing, right? We will do everything that we can to never have an upside-down company. We're focused on trying to match our commercial effort to the opportunity that realistically is right in front of us. And given the value that we're delivering and the efficient manufacturing that we can talk about another time, I suppose, we're very comfortable with the belief that we can develop a uniquely favorable financial profile, one that hasn't been seen in the industry. Why? Because the cost of goods is lower than it's ever been. The efficiency of our standard, well-characterized manufacturing, every patient is getting their cells. Maybe we had one out of 110 or so that we've manufactured who didn't end up getting cells for a weird reason related to the nature of their cells, but just about every patient is getting the product. No company's ever done that, so all of the thoughts that all of us have, that we all harbor, the fears of autologous CAR-T business models have all fallen away one at a time. And as a result, we're really bullish, and we really look forward to talking, now that we have our clinical data out there, about our commercial prospects, about our commercial model. Pediatric myositis first. Adult myositis comes in without the same urgency. If you're 40 years old and you have dermatomyositis, you know, I want the CAR-T therapy, but next time I have an exacerbation, I'll go get it. I don't think those patients are running into their doctor's office to say, did you read the paper? I want that right away. Right? That's a different profile, but that's fine because we need to launch first through this very urgent need that is the juvenile and simultaneous approval, we hope, if the data permit, into the adult myositis population. And by the time we work our way through the juvenile and early adult, scleroderma is going to come right behind it. Scleroderma, recent epidemiology out of ACR. Published by the leading group in the world, 150,000 people with scleroderma in the U.S., 20,000 new patients, incident population in the U.S. every year. Maybe it's 7,000, 8,000 a year who have progressive, serious, moderate to severe progression of their scleroderma. You don't need a lot of patients if you're priced as the new autoimmune drugs that are being used in myositis. You don't need to price very high to have very large revenue numbers when you're treating so few patients, right? So you have to think about the business model in today's terms. With today's pricing of drugs that are given every year, we're a one-time therapy that has durability. We like our odds, and we're excited, frankly, to share a lot more about that over time.

Roger Song, Analyst — Jefferies

Okay, on that point, the one-time treatment, we just want to set the right expectation. What could be the very attractive durability for a very deep response early on?

Stephen, CEO

That's a great question. So I'm smiling because at ACR, I spent probably six hours one day with York Shett, who, of course, we easily considered the father of the autoimmune CAR-T industry. And the first hour or two, we compared data. We looked at his data. We looked at our data. We looked at the CMAX, the number of copies. We looked at all the aspects of his failure rate, 14.5%, a couple of years in. Our failure rate, probably about 15%. Everything about his safety, our safety, his efficacy, his durability, and ours, layers one on top of the other. And frankly, it was thrilling for him to see that somebody finally, his words, somebody finally replicated what I knew I saw. We have for a long time said that Rezacel was designed exclusively for autoimmunity. It was developed. Exclusively for autoimmunity, and the insights that we bring from not only that relationship and his early successful work, but from a team that is incredible at Cabaleta, who made really rigorous choices directed not at, you know, adopting the fastest means of manufacturing, but adopting the means of manufacturing that Professor Shett was using. Because why? Because we all looked at that data in disbelief. If we could only do that and nothing else, we would change the world. Why would we change anything? And so if you ask yourself, why is Cabaleta matching the Shet data? It's because at every turn, we rejected anything that could add risk to the program, and we stayed true to just replicating what he did. As I said to him, he's one of those lucky humans. He didn't dose fine. He just did it, and it worked perfectly. He thread the needle perfectly. All we are is smart enough to have copied him.

Roger Song, Analyst — Jefferies

Okay, good.

Stephen, CEO

Oh, I'm sorry. His five-year, I wanted to say, his five-year data are, as I said, he has about a 14.5% failure rate. Failure is too strong a word. Breakthrough, right? Everything about our data matches his data. So I don't have more than a year or two of data durability, but I have no reason to believe that anything about our future state is going to be different from what you see with him. I think he's foreshadowing what we're going to deliver, but I need the data to be able to say that. And by the time we file, we will have a couple to a few years of data. Recently, we met with FDA. They gave us a clearance to use the efficacy from our first patient's dose with the earliest manufacturing design as well as the later as comparable for both safety and efficacy. See, that matters a ton to payers because we'll be able to walk in the door on the day of launch with two to three years of data and durability in those patients. So we won't have it launch five years, but I have every reason to believe that we'll have 80, 85 percent durability at five years.

Roger Song, Analyst — Jefferies

Makes sense. All right.

Stephen, CEO

Good.

Roger Song, Analyst — Jefferies

So we talked about those two pivotal programs, potentially work at the label, and then you can start to really build a business case. And another major thing in the autoimmune disease is the conditioning therapy. So you are definitely thinking about it, and then also you're generating some data in certain indications. Tell us about the strategy, and then what's the right indication for the first PC-free regimen?

Stephen, CEO

So we're just intellectually curious, and it would be nice to not even do the study. Nobody's ever really done the study with no PC and compared it to with PC in the same population of patients. It's in two studies sequentially, one after the other. So we did it in pemphigus, but then we did it in lupus first. Why? Because many of the women who enter the trial for CAR-T with preconditioning... Are worried about fertility. Fertility preservation is very, very high on their minds. We all in the industry know that. So it makes perfect sense that if we could get rid of the, particularly the cyclophosphamide, that would be a big step forward for those patients. We designed the study, we got rid of the flu-sci, and we've now done the same dose as we do with preconditioning, and we've now moved into a second dose cohort. We'll report that data in the first part of next year, the first half of next year, when it's robust enough that we can have a way forward, either with or without preconditioning in lupus. But I want to say something that has changed. It was about two months ago, an article appeared in the New England Journal of Medicine. Which summarized the world's experience known to date, where a CAR-T product was administered to a patient who had lupus, or another autoimmune disease, and where, despite the warnings not to become pregnant, 12 women became pregnant. So that's probably 12 out of 500 patients total. 12 normal, healthy babies were born. Their B-cells were normal. Their autoimmune systems were normal. CAR-T is not preventing your ovaries from working. And you have to ask yourself, in a world where they've been warned not to have children, How good they must have felt to be unleashed from their disease, right, released from their disease, to be able to start a family. Because I can't imagine why else so many women would get pregnant so quickly in these trials. So, therefore, the fear that what has been seen at high chronic doses of cyclophosphamide in the treatment of ALL and other diseases, that might bleed over into preconditioning, single dose of cyclophosphamide. Um, it didn't, it was never proven that a single dose of cyclophosphamide in a preconditioning regimen would harm your ovaries or either sex organs, male or female. Um, this demonstrates that at least in these 12, you've got a hundred percent success at having normal babies. Um, and if that's true, then the fear may be ill founded and rejected by the science, in which case we have We have to ask ourselves, why not go forward with a 100% response rate at one year off of all medicines? In refractory lupus patients, lupus nephritis, actually, why not go forward to prevent kidney failure in patients who otherwise are going to end up in kidney failure? So internally at the company, we're having an awful lot of discussion about whether to go forward or whether, frankly, it's right to not go forward. The other thing that's changed is we were way behind in lupus, right? Other large companies were moving very quickly and with products that we saw as good enough that we would not displace. Things have changed. Right? There's been delays, there's been side effects, et cetera, and our profile is now clear, and we like our profile enough that I think it supports whether or not we should go forward, and a deep assessment about that is ongoing currently, in addition to reporting out and talking about the PC-free regimen in the indications where we've announced we're evaluating it.

Roger Song, Analyst — Jefferies

Got it. I got the changes there, but for the preconditioning free regimen, is that still part of your strategy? And then what could be the case likely is still going to be viable for your protocol team?

Stephen, CEO

So, listen, PC-free is everybody's dream. The assumption is it's going to be safer. The assumption is it's about as effective, but if you start to see data that it's either more or less effective, more or less safe, you have to begin to ask yourself whether patients would prefer it, and the unknown for us and for the patients is, is it going to be durable? And I need, it's like having a baby. It takes nine, like there's no way that we're going to know the durability of PC-free in lupus, for example, or lupus nephritis, you know, for at least a year or more. We'll have a sample of patients, single, you know, single-digit number of patients, but that doesn't tell me at one year will I really have the durability I expect across the population and how safe will it be. So those trade-offs, they just require time. And our original thinking was don't develop it with preconditioning because you're going to develop it without. Because with preconditioning, it'll be late to the market. It's not going to be different. Well, now it's differentiated. And we're not that late to the market. And so those things changed. Our hope and the promise of PC free remains, and we just need more data. So that's why we're not putting out one or two patients here or there. We really want to put out enough data that we can all, investors and the company alike, and investigators, look at the data and say, this is the best product to develop for patients. So that's how we're going about it.

Roger Song, Analyst — Jefferies

Got it. Okay. And then in that regard, I believe you have a lot of data already from FLE, and then PV is more preconditioned and free. So is that possible you start to push forward FLE as the third pivotal indication because you already got alignment?

Stephen, CEO

Yeah. So we do have alignment with FDA already around the design of that protocol. The biopsies that we demonstrated, which are part and parcel of the definition of Doris, right? Doris, you can have proteinuria as long as it's not due to the lupus nephritis. You need a biopsy to prove that. Right? So as long as our protocol matches and as long as we make the strategic choice to move forward, if we do, that's a trial that could potentially start up next year. So we'll have to wait and see how first the strategic choices and then the regulatory and then the implementation work out.

Roger Song, Analyst — Jefferies

Excellent. Just last minute, on the cash position, you have a lot going on, but how's the financing situation?

Stephen, CEO

So, in the last quarter, we raised about $115 or $120 million. We have about $300 million in the bank at the end of the third quarter, and we're spending about $40 to $50 million per quarter. That brings us into the first quarter of 28, which is about six months, approximately six to nine months, maybe, if you go to the end of the first quarter and the beginning of the third, from the pivotal data being announced. The pivotal data would be announced not only in the adults, but in the children. And in the juvenile cohort, particularly, that PRV is one of the more valuable things that we're keeping our eye on.

Roger Song, Analyst — Jefferies

Excellent. Thank you so much, Stephen. Thank you. Appreciate the time. Thank you, everyone.